Background: The incidence of intrahepatic cholestasis of pregnancy (IHCP) in India is 0.02–2.4% IHCP is the foremost liver disorder, presenting substantial risks and complications to maternal and fetal health. Characterized by pruritus and elevated bile acids and serum transaminases. Materials and Methods: The study focuses on profiling 6 patients of ICP understanding the correlations between liver function tests with serum bile acid and evaluating the impact of ursodeoxycholic acid (UDCA) treatment and also focus on various maternal and fetal outcome. Results: The study identified a predominance of primigravida (83%) of 26–30 years of age (66%), with maximum patients with moderate serum bile acid levels. IHCP diagnosis was commonly noted between 32 and 36.6 weeks GA (66.6%). The treatment with UDCA 300-BD (in 66% of patients) was providing relief to about 66% of participants within a week. Most deliveries occurred between 37 and 39 weeks GA, predominantly through vaginal Deleveries (83%). Post-partum hemorrhage was seen in 33% of patients. Fetal outcomes revealed a 66% incidence of meconium-stained liquor and about 33% neonatal intensive care unit admissions with no fetal mortality. Most participants (83%) had serum bile acid levels in the 10–40 μmoL/L range. Conclusion: Significant correlations were noted between serum glutamate oxaloacetate transaminase and serum glutamate pyruvate transaminase and with alkaline phosphatase and bile acid. In contrast,
bilirubin showed no significant correlations. Higher UDCA dosages showed a dose-response relationship, implying their effectiveness in managing ICP.
Keywords: Intrahepatic cholestasis of pregnancy, serum bile acid, serum glutamate oxaloacetate transaminase, serum
glutamate pyruvate transaminase, ursodeoxycholic acid